Research programme: CD8+ regulatory - T cell therapy

Drug Profile

Research programme: CD8+ regulatory - T cell therapy

Alternative Names: CAR engineered CD8+Treg cells - TxCell; CAR Tregs - TxCell

Latest Information Update: 03 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Center for Research in Transplantation and Immunology
  • Developer Center for Research in Transplantation and Immunology; Inserm Transfert; Nantes University Hospital; TxCell
  • Class Anti-inflammatories; CAR-T cell therapies; Cell therapies; Immunotherapies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Autoimmune disorders; Inflammation; Multiple sclerosis; Transplant rejection

Most Recent Events

  • 19 Jun 2017 TxCell and Lentigen Technology agree to manufacture HLA-A2 CAR lentiviral vector for the CAR-Treg product for Transplant rejection
  • 02 May 2017 TxCell and Inserm Transfert agree to co-develop CD8+ regulatory - T cell therapy for Transplant rejection and Multiple sclerosis
  • 02 May 2017 Preclinical trials in Multiple sclerosis in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top